-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ADC is composed of a monoclonal antibody (Antibody) targeting a specific antigen or tumor-associated antigen, a cytotoxin (Payload) and a linker (linker) connecting the antibody and the cytotox.
This structure allows ADC drugs to combine the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting of antibody dru.
Among them, the antibody is responsible for finding tumor cells, the linker allows the antibody to be entrained, and the toxic small molecules are brought into the tumor cells, and the cytotoxin is a sharp sword to kill the tumor cel.
The industry said that in recent years, the wave of ADC drugs has swept across the country, and companies have been enthusiastic and cooperated continuously, making every effort to overcome the research and development problems of ADC drugs, and continue to make new progre.
For example, on May 24, Huadong Medicine announced that the Biologics License Application (BLA) for Mirvetuximab Soravtansine, a new ADC drug under development jointly developed by the company and ImmunoGen, I.
, has been accepted by the.
Food and Drug Administration (FDA) for single drug use Treatment of platinum-resistant ovarian cancer with high expression of folate receptor alpha (FRα), and was granted priority review stat.
Huadong Medicine stated that Mirvetuximab Soravtansine is a FRα-targeted ADC drug, and it is also a key product under development in the company's innovative tumor drug pipeli.
The acceptance of the BLA application in the United States is an important milestone in the research and development process of this new drug, which will help to promote its approval and marketing process in the United States and has a positive impact on its approval and marketing in Chi.
The company will continue to make every effort to carry out the clinical development and registration of this product in China, and promote it to benefit Chinese ovarian cancer patients as soon as possib.
It is understood that in recent years, Huadong Medicine has continued to increase its differentiated and in-depth layout in the ADC fie.
It has successively invested in the antibody R&D and production company Quanxin Bio, and the ADC linker and conjugation technology company Noring Bio, and has incubated a complete portfolio of ADC drug toxin raw materia.
The product line of Huida Bio, which holds a multi-antibody platform-based R&D company Doer Bio, has carried out equity investment and product cooperation with HeidelbergPharma, a global emerging technology company in the ADC field, to form the global R&D ecosystem of Huadong Medicine A.
In addition, there were several developments in ADC drugs in Apr.
For example, on April 27, ENHERTU, an innovative ADC drug jointly developed by Daiichi Sankyo .
, L.
and AstraZeneca for the treatment of HER2-low breast cancer, was granted breakthrough therapy designation (BTD) by the F.
Enhertu has now received five Breakthrough Therapy Designations, three for breast cancer, one for lung cancer and one for gastric canc.
Meanwhile, on April 24, ENHERTU was also included in priority review by C.
At the end of April, YL201, an innovative ADC (Antibody–Drug Conjugates) drug independently developed by Medilink Therapeutics, obtained the implied approval of the US FDA for clinical tria.
The data shows that the YL201 project has completely independent intellectual property rights, and the toxin and linker are innovative structur.
Preclinical data show that it can effectively inhibit the growth of various tumors and has good toleran.
Explore studies in indications such as non-small cell lung cancer, prostate cancer and esophageal squamous cell carcino.
On April 19, Connoya announced that its new drug, CMG901, for the treatment of relapsed/refractory gastric cancer and gastroesophageal junction adenocarcinoma (GC/GEJC) has recently been granted Fast Track by the.
F.
Qualification (FT.
CMG901 is an antibody-drug conjugate (ADC) targeting Claudin12, containing a Claudin12-specific antibody, a cleavable linker and a toxic load-methyl auristatin E (MMAE), which is obtained in both China and the United States Approved Claudin12 antibody conjugated drug for clinical trial applicati.
The industry said that after years of development, ADC drugs are finally entering the harvest peri.
With the iteration and maturity of ADC technology, the ADC treatment window will become larger, and there will be more and more clinical data displayed by ADC drugs that have been marketed or are under developme.
Very excellent, more and more new targets will be used for ADC development in the future, helping ADC become a platform method for tumor treatme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
This structure allows ADC drugs to combine the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting of antibody dru.
Among them, the antibody is responsible for finding tumor cells, the linker allows the antibody to be entrained, and the toxic small molecules are brought into the tumor cells, and the cytotoxin is a sharp sword to kill the tumor cel.
The industry said that in recent years, the wave of ADC drugs has swept across the country, and companies have been enthusiastic and cooperated continuously, making every effort to overcome the research and development problems of ADC drugs, and continue to make new progre.
For example, on May 24, Huadong Medicine announced that the Biologics License Application (BLA) for Mirvetuximab Soravtansine, a new ADC drug under development jointly developed by the company and ImmunoGen, I.
, has been accepted by the.
Food and Drug Administration (FDA) for single drug use Treatment of platinum-resistant ovarian cancer with high expression of folate receptor alpha (FRα), and was granted priority review stat.
Huadong Medicine stated that Mirvetuximab Soravtansine is a FRα-targeted ADC drug, and it is also a key product under development in the company's innovative tumor drug pipeli.
The acceptance of the BLA application in the United States is an important milestone in the research and development process of this new drug, which will help to promote its approval and marketing process in the United States and has a positive impact on its approval and marketing in Chi.
The company will continue to make every effort to carry out the clinical development and registration of this product in China, and promote it to benefit Chinese ovarian cancer patients as soon as possib.
It is understood that in recent years, Huadong Medicine has continued to increase its differentiated and in-depth layout in the ADC fie.
It has successively invested in the antibody R&D and production company Quanxin Bio, and the ADC linker and conjugation technology company Noring Bio, and has incubated a complete portfolio of ADC drug toxin raw materia.
The product line of Huida Bio, which holds a multi-antibody platform-based R&D company Doer Bio, has carried out equity investment and product cooperation with HeidelbergPharma, a global emerging technology company in the ADC field, to form the global R&D ecosystem of Huadong Medicine A.
In addition, there were several developments in ADC drugs in Apr.
For example, on April 27, ENHERTU, an innovative ADC drug jointly developed by Daiichi Sankyo .
, L.
and AstraZeneca for the treatment of HER2-low breast cancer, was granted breakthrough therapy designation (BTD) by the F.
Enhertu has now received five Breakthrough Therapy Designations, three for breast cancer, one for lung cancer and one for gastric canc.
Meanwhile, on April 24, ENHERTU was also included in priority review by C.
At the end of April, YL201, an innovative ADC (Antibody–Drug Conjugates) drug independently developed by Medilink Therapeutics, obtained the implied approval of the US FDA for clinical tria.
The data shows that the YL201 project has completely independent intellectual property rights, and the toxin and linker are innovative structur.
Preclinical data show that it can effectively inhibit the growth of various tumors and has good toleran.
Explore studies in indications such as non-small cell lung cancer, prostate cancer and esophageal squamous cell carcino.
On April 19, Connoya announced that its new drug, CMG901, for the treatment of relapsed/refractory gastric cancer and gastroesophageal junction adenocarcinoma (GC/GEJC) has recently been granted Fast Track by the.
F.
Qualification (FT.
CMG901 is an antibody-drug conjugate (ADC) targeting Claudin12, containing a Claudin12-specific antibody, a cleavable linker and a toxic load-methyl auristatin E (MMAE), which is obtained in both China and the United States Approved Claudin12 antibody conjugated drug for clinical trial applicati.
The industry said that after years of development, ADC drugs are finally entering the harvest peri.
With the iteration and maturity of ADC technology, the ADC treatment window will become larger, and there will be more and more clinical data displayed by ADC drugs that have been marketed or are under developme.
Very excellent, more and more new targets will be used for ADC development in the future, helping ADC become a platform method for tumor treatme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
